Wegovy 9mg GLP-1 Pill, 30 Tablets, for Weight Loss Support

Wegovy 9mg Tablets are a once-daily, prescription-only oral GLP-1 receptor agonist treatment containing semaglutide, developed by Novo Nordisk to support adults living with obesity or overweight with weight-related health conditions. Designed as part of a comprehensive medical weight management program, Wegovy® Pill helps support clinically proven and sustainable weight loss when combined with a balanced diet and increased physical activity. Containing semaglutide, a molecule backed by more than 8 years of clinical studies and real-world experience in diabetes and weight management, Wegovy® Pill works with the body's natural mechanisms by reducing appetite, increasing feelings of fullness, and helping individuals consume less over time. Its established safety profile and extensive clinical evidence make it a trusted option for long-term weight management.

The 9mg strength represents the second dose-escalation stage following the initial 1.5mg and 4mg phases. The once-daily oral tablet offers a convenient alternative to injectable GLP-1 therapies, making it suitable for individuals who prefer oral treatment. Taken in the morning on an empty stomach with a sip of water and followed by a 30-minute waiting period before eating or drinking, Wegovy® Pill is designed to fit easily into daily routines and support treatment adherence.

Benefits

• Contains semaglutide, a GLP-1 receptor agonist with over 8 years of clinical experience.
• Once-daily tablet format provides an alternative to injectable GLP-1 therapies.
• Works with the body's natural mechanisms to reduce appetite and enhance feelings of fullness.
• Designed to support clinically proven, gradual, and sustainable weight management.
• Can be incorporated into a simple morning routine.
• Intended for long-term use as part of a medical weight management program.
• No injections required, making administration convenient for those with an oral preference.
• Clinical studies reported average weight reduction of approximately 17%, with some participants achieving 20% or greater weight loss.
• Established safety profile consistent with the GLP-1 receptor agonist class.

Suggested Usage : Wegovy 9mg Tablets should only be used under the supervision of a healthcare professional. During the second dose-escalation phase, take one tablet once daily in the morning on an empty stomach with up to half a cup of water. Wait at least 30 minutes before eating, drinking, or taking other oral medications. Each dose level is typically maintained for approximately 30 days before progressing according to your prescribed treatment plan.

Suitable For

• Adults aged 18 years and above.
• Individuals living with obesity.
• Adults who are overweight and have weight-related health conditions.
• People who prefer oral tablets over injectable treatments.
• Individuals seeking a physician-supervised weight management approach.
• Those committed to combining treatment with balanced nutrition and increased physical activity.
• Not suitable for individuals with hypersensitivity to semaglutide or any formulation components.

Product Specifications